Prognostic value of KRAS mutations, TP53 mutations and PD-L1 expression among lung adenocarcinomas treated with immunotherapy | Journal of Clinical Pathology

Subscribe
Log In More

Log in via Institution
Log in via OpenAthens
Log in via ACP

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Current issue

Archive

Authors

About
Subscribe
Log in More

Log in via Institution
Log in via OpenAthens
Log in via ACP

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Citation Tools

Original research

Prognostic value of KRAS mutations, TP53 mutations and PD-L1 expression among lung adenocarcinomas treated with immunotherapy

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:: Tønnesen EMT, Stougaard M, Meldgaard P, et al

Prognostic value of KRAS mutations, TP53 mutations and PD-L1 expression among lung adenocarcinomas treated with immunotherapy

Journal of Clinical Pathology Published Online First: 21 November 2022. doi: 10.1136/jcp-2022-208574